Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

Overview of attention for article published in New England Journal of Medicine, November 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 32 news outlets
blogs: 11 blogs
policy: 5 policy sources
twitter: 125 X users
patent: 32 patents

facebook: 12 Facebook pages
wikipedia: 11 Wikipedia pages
reddit: 3 Redditors
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 1781 Mendeley

So far, Altmetric has seen 42 news stories from 32 outlets.

Dubbelt positivt för behandling vid svår muskelsjukdom

Dagens Medicin, 26 Sep 2026

Två studier publicerade i New England Journal of Medicine visar hoppfulla resultat för den dödliga sjukdomen spinal muskelatrofi.

筋強直性ジストロフィーを根本から治療できるか

Medical Tribune, 14 Aug 2026

研究の背景：標的臓器に薬剤を到達させる技術が鍵筋強直性ジストロフィー1型（DM1）は、成人で最も頻度の高い筋ジストロフィーであり、国内の有病率は10万人当たり9～10人と推測される〔難病情報センター（2026年8月4日時点）〕。また、国内の筋疾患患者レジス…

The Spinraza therapy - Biogen Inc. leans on long-term SMA demand

Ad Hoc News, 01 Jul 2026

By Nora Whitfield, ad hoc news Accessories

Antisense-Wirkstoffe: Neue Hoffnung bei unheilbaren Gehirnerkrankungen

Spektrum, 14 Apr 2021

Antisense-Wirkstoffe: Neue Hoffnung bei unheilbaren Gehirnerkrankungen Zu viel vom falschen Protein - zu wenig vom guten…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 38 additional news stories.